N/A
Completed N=10
Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring
Acne Scars - Mixed Atrophic and Hypertrophic
Source: ClinicalTrials.gov NCT04606134 ↗
Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Apr 2023
Primary outcomePrimary: Mean Change From Baseline in Erythema — -1.687; 5.730 units on a scale
Summary
To evaluate the efficacy of a tripeptide/hexapeptide topical (Alastin Regenerating Skin Nectar with TriHex Technology®) in wound healing and scar reduction following Erbium:YAG hybrid resurfacing laser for acne scarring compared to the standard of post-procedure care consisting of a bland moisturizer.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Change From Baseline in Erythema |
1.768; 5.596 | — |
| SECONDARY Mean Change in Skin Barrier Function |
6.502; 21.59; 2.858; 39.07 | — |
| SECONDARY Number of Participants Who Scored Skin Appearance as no Change, Improved or Much Improved Using the Global Aesthetic Improvement Scale |
4; 1; 2; 1; 0; 1 | — |
Eligibility Criteria
Inclusion Criteria
- male or females
- age 18 and older
- with evidence of grade II-III acne scars on the face (mild to moderate) as determined by the Goodman & Baron qualitative global acne scar grading system
Exclusion Criteria
- treatment to face with any energy device within 6 months
- tanning within 7 days
- dermabrasion or chemical peel within 3 months
- current use of systemic retinoids
- keloidal scaring in the treatment area
- use of systemic steroids within 6 months
- use of topical products with retinoid, alpha-hydroxyacid, salicylic acid, vitamin C or E within 14 days
Data sourced from ClinicalTrials.gov (NCT04606134). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.